User
Favorite list
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Early access program to fully automated, cyclic, high-content immunofluorescence-based imaging
BERGISCH GLADBACH, March 28, 2019 – Miltenyi Biotec, a global provider of products and services for biomedical research and cellular therapy, introduces its new platform for fully automated, ultrahigh-content imaging at the AACR Annual Meeting 2019 in Atlanta, USA: the MACSima™ Imaging Platform.
The MACSima™ Imaging Platform is the latest addition to Miltenyi Biotec’s imaging portfolio and will be presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA (from March 31, 2019, at booth 2936). The benchtop instrument performs a fully automated iterative fluorescent staining, imaging, and signal erasing process, using multiple fluorochrome-conjugated antibodies per cycle. A harmonized portfolio including Miltenyi Biotec’s range of validated antibodies, e.g., REAfinity™ Recombinant Antibodies, specifically designed disposables, and the MACSima™ Software ensure a failure-free automated process. Resulting image stacks can then be analyzed on the fly, even when the iterative process is still running. Basic and biomedical research, specifically drug-target and biomarker discovery as well as deep phenotyping, will be the major fields of application. Based on a revolutionary technology, this platform enables the simultaneous analysis of an unprecedented number of markers in a single sample, even on a desired sample area. Various fixed sample types can be used as starting material.
“Using the MACSima™ Imaging Platform, it is now possible to stain and analyze hundreds of markers on a single sample, whereas so far, researchers were limited to only a few markers. Imagine a situation where you have only three pieces of a large puzzle. The new MACSima™ Platform enables you to get all the missing pieces so you can understand the whole picture”, states Dr. Andreas Bosio, Head of Miltenyi Biotec´s Imaging Development Program.
Early access program available
Attendees of the AACR Annual Meeting will be the first to get a chance to take a look at Miltenyi Biotec’s new MACSima™ Imaging Platform. Researchers interested in the technology will have the opportunity to sign up for the early access program.
Miltenyi Biotec recently acquired the microscopy specialist LaVision BioTec GmbH, and imaging solution manufacturer Sensovation AG, expanding its range of products for cell analysis and imaging.
More information on the MACSima™ Imaging Platform will be available online starting April 1, 2019.
About Miltenyi Biotec
Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support research from basic research to translational research to clinical application. Our 30 years of expertise includes immunology, stem cell biology, neuroscience, and cancer. Miltenyi Biotec has 2,500 employees in 28 countries.
Miltenyi Biotec media contact
Dr. Anja Kohmann
Miltenyi Biotec GmbH
press@miltenyibiotec.de
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.
